INSIGHTS FROM TRANSGENIC MICE REGARDING THE ROLE OF BCL-2 IN NORMAL AND NEOPLASTIC LYMPHOID-CELLS

被引:34
作者
CORY, S
HARRIS, AW
STRASSER, A
机构
[1] Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria
关键词
D O I
10.1098/rstb.1994.0108
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The bcl-2 gene was first discovered by molecular analysis of the 14;18 chromosome translocation which is the hallmark of most cases of human follicular lymphoma. To date, it is unique among proto-oncogenes because, rather than promoting cell proliferation, it fosters cell survival. This review summarizes the impact of constitutive bcl-2 expression on the development and function of lymphocytes as well as their malignant transformation. Expression of a bcl-2 transgene in the B lymphoid compartment profoundly perturbed homeostasis and, depending on the genetic background, predisposed to a severe autoimmune disease resembling human systemic lupus erythematosus. T lymphoid cells from bcl-2 transgenic mice were remarkably resistant to diverse cytotoxic agents. Nevertheless, T lymphoid homeostasis was unaffected and tolerance to self was maintained. Expression of high levels of Bcl-2 facilitated the development of B lymphoid tumours but at relatively low frequency and with long latency. Co-expression of myc and bcl-2, on the other hand, promoted the rapid onset of novel tumours which appeared to derive from a lympho-myeloid stem or progenitor cell. Introduction of the bcl-2 transgene into scid mice facilitated the survival and differentiation of pro-B but not pro-T cells, suggesting that a function necessary to supplement or complement the action of Bcl-2 is expressed later in the T than the B lineage. Crosses of the bcl-2 transgenic mice with p53(-/-) mice have addressed whether loss of p53 function and gain of bcl-2 function are synergistic for lymphoid cell survival.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 69 条
  • [21] CAENORHABDITIS-ELEGANS GENE CED-9 PROTECTS CELLS FROM PROGRAMMED CELL-DEATH
    HENGARTNER, MO
    ELLIS, RE
    HORVITZ, HR
    [J]. NATURE, 1992, 356 (6369) : 494 - 499
  • [22] BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH
    HOCKENBERY, D
    NUNEZ, G
    MILLIMAN, C
    SCHREIBER, RD
    KORSMEYER, SJ
    [J]. NATURE, 1990, 348 (6299) : 334 - 336
  • [23] BCL2 PROTEIN IS TOPOGRAPHICALLY RESTRICTED IN TISSUES CHARACTERIZED BY APOPTOTIC CELL-DEATH
    HOCKENBERY, DM
    ZUTTER, M
    HICKEY, W
    NAHM, M
    KORSMEYER, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) : 6961 - 6965
  • [24] THE NATURAL-HISTORY OF INITIALLY UNTREATED LOW-GRADE NON-HODGKINS LYMPHOMAS
    HORNING, SJ
    ROSENBERG, SA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (23) : 1471 - 1475
  • [25] TUMOR SPECTRUM ANALYSIS IN P53-MUTANT MICE
    JACKS, T
    REMINGTON, L
    WILLIAMS, BO
    SCHMITT, EM
    HALACHMI, S
    BRONSON, RT
    WEINBERG, RA
    [J]. CURRENT BIOLOGY, 1994, 4 (01) : 1 - 7
  • [26] A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA
    KASTAN, MB
    ZHAN, QM
    ELDEIRY, WS
    CARRIER, F
    JACKS, T
    WALSH, WV
    PLUNKETT, BS
    VOGELSTEIN, B
    FORNACE, AJ
    [J]. CELL, 1992, 71 (04) : 587 - 597
  • [27] KASTAN MB, 1991, CANCER RES, V51, P6304
  • [28] CANCER - P53, GUARDIAN OF THE GENOME
    LANE, DP
    [J]. NATURE, 1992, 358 (6381) : 15 - 16
  • [29] LANGDON WY, 1988, ONCOGENE RES, V3, P271
  • [30] SEQUENTIAL BCL-2 AND C-MYC ONCOGENE REARRANGEMENTS ASSOCIATED WITH THE CLINICAL-TRANSFORMATION OF NON-HODGKINS LYMPHOMA
    LEE, JT
    INNES, DJ
    WILLIAMS, ME
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) : 1454 - 1459